A new phage-display tumor-homing peptide fused to antiangiogenic peptide generates a novel bioactive molecule with antimelanoma activity

Molecular Cancer Research

Volumn 9, Issue 11, 2011, Pages 1471-1478

  Matsuo, Alisson L ^a   Juliano, Maria A ^a   Figueiredo, Carlos R ^a   Batista, Wagner L ^a   Tanaka, Aparecida S ^a   Travassos, Luiz R ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CYCLOPEPTIDE; PEPTIDE LIBRARY; SONIC HEDGEHOG PROTEIN; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VIVO STUDY; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VASCULARIZATION;

AMINO ACID SEQUENCE; ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE LIBRARY; PEPTIDES; RECOMBINANT FUSION PROTEINS; SUBSTRATE SPECIFICITY;

ANIMALIA; ERINACEIDAE; MUS;

EID: 81755181058     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0501     Document Type: Article

References (35)

1. Tawbi HA, Buch SC.Chemotherapy resistance abrogation in metastatic melanoma. Clin Adv Hematol Oncol 2010:8:259-66.
2. Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med 2006:355:51-65.
3. Shadidi M, Sioud M. Selective targeting of cancer cells using synthetic peptides. Drug Resist Updat 2003:6:363-71. (Pubitemid 38173587)
4. Zhang Y, Chen J, Zhang Y, Hu Z, Hu D, Pan Y, et al. Panning and identification of a colon tumor binding peptide from a phage display peptide library. J Biomol Screen 2007:12;429-35. (Pubitemid 46514673)
5. Kolonin MG, Sun J, Do KA, Vidal CI, Ji Y, Baggerly KA, et al. Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J 2006:20;979-81.
6. Hu S, Guo X, Xie H, Du Y, Pan Y, Shi Y, et al. Phage display selection of peptides that inhibit metastasis ability of gastric cancer cells with high liver-metastatic potential. Biochem Biophys Res Commun 2006:341: 964-72. (Pubitemid 43221760)
7. Li XB, Schluesener HJ, Xu SQ. Molecular addresses of tumors: selection by in vivo phage display. Arch Immunol Ther Exp (Warsz) 2006:54:177-181. (Pubitemid 44257338)
8. Pasqualini R, Arap W, McDonald DM. Probing the structural and molecular diversity of tumor vasculature. Trends Mol Med 2002:8: 563-71. (Pubitemid 35408214)
9. Ladner RC, Sato AK, Gorzelany J, de Souza M. Phage display-derived peptides as therapeutic alternatives to antibodies. Drug Discov Today 2004:9:525-29. (Pubitemid 38739333)
10. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998:279; 377-80. (Pubitemid 28063372)
11. Hetian L, Ping A, Shumei S, Xiaoying L, Luowen H, Jian W, et al. A novel peptide isolated from a phage display library inhibits tumor growth and metastasis by blocking the binding of vascular endothelial growth factor to its kinase domain receptor. J Biol Chem 2002:277; 43137-42. (Pubitemid 35285698)
12. Bussolati B, Grange C, Tei L, Deregibus MC, Ercolani M, Aime S, et al. Targeting of human renal tumor-derived endothelial cells with peptides obtained by phage display. J Mol Med 2007:85: 897-906. (Pubitemid 47077113)
13. Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MA, et al. Tumor specific phage particles promote tumor regression in a mouse melanoma model. Cancer Immunol Immunother 2007:56:677-87. (Pubitemid 46348740)
14. Howell RC, Revskaya E, Pazo V, Nosanchuk JD, Casadevall A, Dadachova E, et al. Phage display library derived peptides that bind to human tumor melanin as potential vehicles for targeted radionuclide therapy of metastatic melanoma. Bioconjug Chem 2007:18;1739-48. (Pubitemid 350219971)
15. Wu J, Wu MC, Zhang LF, Lei JY, Feng L, Jin J, et al. Identification of binding peptides of the ADAM15 disintegrin domain using phage display. J Biosci 2009:34:213-20.
16. Matsuo AL, Tanaka AS, Juliano MA, Rodrigues EG, Travassos LR. A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity. J Mol Med 2010:88:1255-64.
17. Dobroff AS, Rodrigues EG, Juliano MA, Fria̧ca DM, Nakayasu ES, Almeida IC, et al. Differential antitumor effects of IgG and IgM monoclonal antibodies and their synthetic complementarity-determining regions directed to new targets of B16F10-Nex2 melanoma cells. Transl Oncol 2010:3:204-17.
18. Rodrigues EG, Silva LS, Fausto DM, Hayashi MS, Dreher S, Santos EL, et al. Cyclopalladated compounds as chemotherapeutic agents: antitumor activity against a murine melanoma cell line. Int J Cancer 2003:107;498-504. (Pubitemid 37266473)
19. Bhutia SK, Maiti TK. Targeting tumors with peptides from natural sources. Trends Biotechnol 2008:26;210-7.
20. Polonelli L, Pontón J, Elguezabal N, Moragues MD, Casoli C, Pilotti E, et al. Antibody complementarity-determining regions (CDRs) can display differential antimicrobial, antiviral and antitumor activities. PLoS One 2008:3:e2371.
21. Zou J, Dickerson MT, Owen NK, Landon LA, Deutscher SL. Biodistribution of filamentous phage peptide libraries in mice. Mol Biol Rep 2004:31:121-29. (Pubitemid 38881802)
22. Samanta S, Sistla R, Chaudhuri A. The use of RGDGWK-lipopeptide to selectively deliver genes to mouse tumor vasculature and its complexation with p53 to inhibit tumor growth. Biomaterials 2010: 31:1787-97.
23. Yang RB, Ng CK, Wasserman SM, Colman SD, Shenoy S, Mehraban F, et al. Identification of a novel family of cell-surface proteins expressed in human vascular endothelium. J Biol Chem 2002:277; 46364-73. (Pubitemid 35417631)
24. Tsai MT, Cheng CJ, Lin YC, Chen CC, Wu AR, Wu MT, et al. Isolation and characterization of a secreted, cell-surface glycoprotein SCUBE2 from humans. Biochem J 2009:422;119-28.
25. Rubin LL, de Sauvage FJ.Targeting the Hedgehog pathway in cancer. Nat Rev Drug Discov 2006:5:1026-33. (Pubitemid 44835129)
26. Kasper M, Jaks V, Fiaschi M, Toftga- rd R. Hedgehog signalling in breast cancer. Carcinogenesis 2009:30:903-11.
27. Li C, Chi S, Xie J, Hedgehog signaling in skin cancers. Cell Signal 2011:23;1235-43.
28. Geng L, Cuneo KC, Cooper MK, Wang H, Sekhar K, Fu A, et al. Hedgehog signaling in the murine melanoma microenvironment. Angiogenesis 2007:10;259-67. (Pubitemid 350045881)
29. Furuya M, Yonemitsu Y, Aoki I III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des 2009:15; 1854-67.
30. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 2003: 3:411-21. (Pubitemid 37328845)
31. Boehm S, Rothermundt C, Hess D, Joerger M. Antiangiogenic drugs in oncology: a focus on drug safety and the elderly - a mini-review. Gerontology 2010:56:303-9.
32. Matthews W, Jordan CT, Gavin M, Jenkins NA, Copeland NG, Lemischka IR, et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci U S A 1991:88: 9026-30. (Pubitemid 21915561)
33. Guo S, Colbert LS, Fuller M, Zhang Y, Gonzalez-Perez RR. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim Biophys Acta 2010:1806;108-121.
34. Kou B, Li Y, Zhang L, Zhu G, Wang X, Li Y, et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp Mol Pathol 2004:76:129-37. (Pubitemid 38316928)
35. Bidwell GL III, Raucher D.Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. Expert Opin Drug Deliv 2009:6:1033-47.